Search by Drug Name or NDC
NDC 75854-0343-60 Nicomide 100; 2; 500; 750; 50; 27 ug/1; mg/1; ug/1; mg/1; ug/1; mg/1 Details
Nicomide 100; 2; 500; 750; 50; 27 ug/1; mg/1; ug/1; mg/1; ug/1; mg/1
Nicomide is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Avion Pharmaceuticals, LLC. The primary component is CHROMIUM; CUPRIC OXIDE; FOLIC ACID; NIACINAMIDE; SELENIUM; ZINC GLYCINATE.
Product Information
| NDC | 75854-0343 |
|---|---|
| Product ID | 75854-343_1bdbe782-d27b-425b-b48b-c2d08daee019 |
| Associated GPIs | 78104920000320 |
| GCN Sequence Number | 073170 |
| GCN Sequence Number Description | lmefolate/B3/copp/Zn/sel/chrom TABLET 0.5-750 MG ORAL |
| HIC3 | C6Z |
| HIC3 Description | MULTIVITAMIN PREPARATIONS |
| GCN | 37533 |
| HICL Sequence Number | 041605 |
| HICL Sequence Number Description | LEVOMEFOLATE CALC/NIACINAMIDE/COPPER/ZINC/SELENIUM/CHROMIUM |
| Brand/Generic | Brand |
| Proprietary Name | Nicomide |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | niacinamide, zinc glycinate, folic acid, cupric oxide, selenium and chromium |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 100; 2; 500; 750; 50; 27 |
| Active Ingredient Units | ug/1; mg/1; ug/1; mg/1; ug/1; mg/1 |
| Substance Name | CHROMIUM; CUPRIC OXIDE; FOLIC ACID; NIACINAMIDE; SELENIUM; ZINC GLYCINATE |
| Labeler Name | Avion Pharmaceuticals, LLC |
| Pharmaceutical Class | Allergens [CS], Cell-mediated Immunity [PE], Copper Absorption Inhibitor [EPC], Decreased Copper Ion Absorption [PE], Increased Histamine Release [PE], Standardized Chemical Allergen [EPC] |
| DEA Schedule | n/a |
| Marketing Category | UNAPPROVED DRUG OTHER |
| Application Number | n/a |
| Listing Certified Through | 2024-12-31 |
Package
NDC 75854-0343-60 (75854034360)
| NDC Package Code | 75854-343-60 |
|---|---|
| Billing NDC | 75854034360 |
| Package | 60 TABLET in 1 BOTTLE (75854-343-60) |
| Marketing Start Date | 2014-12-08 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |